首页 > 最新文献

Thrombosis Journal最新文献

英文 中文
Prophylaxis with enoxaparin and antithrombin III in drug-induced coagulation alterations in childhood leukemia: a retrospective experience of 20 years. 使用依诺肝素和抗凝血酶 III 预防药物诱发的儿童白血病凝血功能改变:20 年的回顾性经验。
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-03-27 DOI: 10.1186/s12959-024-00602-x
Christina Salvador, Robert Salvador, Gabriele Kropshofer, Bernhard Meister, Marie Rock, Petra Obexer, Benjamin Hetzer, Evelyn Rabensteiner, Roman Crazzolara

Background: Thromboembolic complications are well known in the treatment of childhood acute lymphoblastic leukemia. Over the years it has not been possible to reach a consensus on a possible prophylaxis of thromboembolic events during intensive therapy. Only the administration of enoxaparin was able to achieve evidence in the literature to date.

Methods: In this retrospective study, 173 childhood leukemia patients were treated over 20 years with a thromboembolic prophylaxis including enoxaparin and AT III during induction therapy with L-asparaginase and cortisone.

Results: We here report the effectiveness of administration of enoxaparin and AT III in childhood leukemia, showing a strikingly low prevalence of deep vein thrombosis (2.9%). Especially in adolescent patients, a particularly great need for AT III was demonstrated.

Conclusions: We recommend thromboembolic prophylaxis with enoxaparin and AT III substitution during induction/reinduction therapy with L-asparaginase and glucocorticosteroids, especially from adolescence onwards.

背景:血栓栓塞并发症在儿童急性淋巴细胞白血病的治疗中是众所周知的。多年来,人们一直未能就强化治疗期间预防血栓栓塞事件的可能性达成共识。迄今为止,只有服用依诺肝素能够在文献中获得证据:在这项回顾性研究中,173 名儿童白血病患者在接受 L-天冬酰胺酶和可的松诱导治疗期间接受了长达 20 年的血栓栓塞预防治疗,包括依诺肝素和 AT III:我们在此报告在儿童白血病患者中使用依诺肝素和 AT III 的效果,结果显示深静脉血栓的发生率非常低(2.9%)。结论:我们建议儿童白血病患者进行血栓栓塞预防:我们建议在使用 L-天冬酰胺酶和糖皮质激素进行诱导/还原治疗期间,使用依诺肝素和 AT III 进行血栓栓塞预防,尤其是从青春期开始。
{"title":"Prophylaxis with enoxaparin and antithrombin III in drug-induced coagulation alterations in childhood leukemia: a retrospective experience of 20 years.","authors":"Christina Salvador, Robert Salvador, Gabriele Kropshofer, Bernhard Meister, Marie Rock, Petra Obexer, Benjamin Hetzer, Evelyn Rabensteiner, Roman Crazzolara","doi":"10.1186/s12959-024-00602-x","DOIUrl":"10.1186/s12959-024-00602-x","url":null,"abstract":"<p><strong>Background: </strong>Thromboembolic complications are well known in the treatment of childhood acute lymphoblastic leukemia. Over the years it has not been possible to reach a consensus on a possible prophylaxis of thromboembolic events during intensive therapy. Only the administration of enoxaparin was able to achieve evidence in the literature to date.</p><p><strong>Methods: </strong>In this retrospective study, 173 childhood leukemia patients were treated over 20 years with a thromboembolic prophylaxis including enoxaparin and AT III during induction therapy with L-asparaginase and cortisone.</p><p><strong>Results: </strong>We here report the effectiveness of administration of enoxaparin and AT III in childhood leukemia, showing a strikingly low prevalence of deep vein thrombosis (2.9%). Especially in adolescent patients, a particularly great need for AT III was demonstrated.</p><p><strong>Conclusions: </strong>We recommend thromboembolic prophylaxis with enoxaparin and AT III substitution during induction/reinduction therapy with L-asparaginase and glucocorticosteroids, especially from adolescence onwards.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"22 1","pages":"30"},"PeriodicalIF":3.1,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10976720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal damage and old age: risk factors for thrombosis in patients with ANCA-associated vasculitis 肾损伤和高龄:ANCA 相关性血管炎患者血栓形成的风险因素
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-03-20 DOI: 10.1186/s12959-024-00593-9
Xin Chen, Shuo Zhang, Ruilian You, Yixin Ma, Peng Xia, Xiaoxiao Shi, Haiting Wu, Ke Zheng, Yan Qin, Xinping Tian, Limeng Chen
Thrombosis in ANCA-associated vasculitis (AAV) was prevalent and has been neglected in Chinese patients. This study tried to describe the clinical characteristics, identify the risk factors, and investigate the causal relationship between AAV and venous thromboembolism (VTE) by two-sample Mendelian randomization (MR) analysis. In this retrospective, observational study, we included all hospitalized AAV patients from Jan 2013 to Apr 2022 in Peking Union Medical College Hospital. We collected their clinical data for multivariate regression analysis to determine the risk factors for thrombosis. The nomogram was constructed by applying these risk factors to predict thrombosis in AAV patients. As for MR analysis, we selected single nucleotide polymorphisms (SNPs) related to AAV from published genome-wide association studies and extracted the outcome data containing deep vein thrombosis (DVT) and pulmonary embolism (PE) from the UK biobank. 1203 primary AAV patients were enrolled, and thrombosis occurred in 11.3%. Multivariate regression suggested that older than 65 years, EGPA, neurological involvement, lung involvement, significantly elevated serum creatinine (> 500µmol/L), and elevated D-dimer were associated with thrombosis in AAV patients. The model demonstrated satisfied discrimination with an AUC of 0.769 (95% CI, 0.726–0.812). MR analysis showed that EGPA could increase the risk of developing DVT and PE (OR = 1.0038, 95%CI = 1.0035–1.0041, P = 0.009). Thrombosis was not rare in Chinese patients with AAV. Renal damage and old age emerged as critical risk factors for thrombosis. EGPA might have a potential causal relationship with DVT and PE.
ANCA相关性血管炎(AAV)血栓形成在中国患者中普遍存在,但一直被忽视。本研究试图通过双样本孟德尔随机分析法(MR)描述AAV的临床特征、识别风险因素并探讨AAV与静脉血栓栓塞(VTE)之间的因果关系。在这项回顾性观察研究中,我们纳入了 2013 年 1 月至 2022 年 4 月在北京协和医院住院的所有 AAV 患者。我们收集了他们的临床数据进行多变量回归分析,以确定血栓形成的风险因素。应用这些风险因素构建了预测 AAV 患者血栓形成的提名图。至于MR分析,我们从已发表的全基因组关联研究中选择了与AAV相关的单核苷酸多态性(SNPs),并从英国生物库中提取了包含深静脉血栓(DVT)和肺栓塞(PE)的结果数据。共有1203名原发性AAV患者入选,其中11.3%的患者发生了血栓形成。多变量回归表明,年龄大于65岁、EGPA、神经系统受累、肺部受累、血清肌酐明显升高(> 500µmol/L)和D-二聚体升高与AAV患者血栓形成有关。该模型的AUC为0.769(95% CI,0.726-0.812),显示了令人满意的辨别能力。MR分析显示,EGPA可增加发生深静脉血栓和PE的风险(OR = 1.0038,95%CI = 1.0035-1.0041,P = 0.009)。血栓形成在中国 AAV 患者中并不罕见。肾损伤和高龄是血栓形成的关键风险因素。EGPA 可能与深静脉血栓和 PE 有潜在的因果关系。
{"title":"Renal damage and old age: risk factors for thrombosis in patients with ANCA-associated vasculitis","authors":"Xin Chen, Shuo Zhang, Ruilian You, Yixin Ma, Peng Xia, Xiaoxiao Shi, Haiting Wu, Ke Zheng, Yan Qin, Xinping Tian, Limeng Chen","doi":"10.1186/s12959-024-00593-9","DOIUrl":"https://doi.org/10.1186/s12959-024-00593-9","url":null,"abstract":"Thrombosis in ANCA-associated vasculitis (AAV) was prevalent and has been neglected in Chinese patients. This study tried to describe the clinical characteristics, identify the risk factors, and investigate the causal relationship between AAV and venous thromboembolism (VTE) by two-sample Mendelian randomization (MR) analysis. In this retrospective, observational study, we included all hospitalized AAV patients from Jan 2013 to Apr 2022 in Peking Union Medical College Hospital. We collected their clinical data for multivariate regression analysis to determine the risk factors for thrombosis. The nomogram was constructed by applying these risk factors to predict thrombosis in AAV patients. As for MR analysis, we selected single nucleotide polymorphisms (SNPs) related to AAV from published genome-wide association studies and extracted the outcome data containing deep vein thrombosis (DVT) and pulmonary embolism (PE) from the UK biobank. 1203 primary AAV patients were enrolled, and thrombosis occurred in 11.3%. Multivariate regression suggested that older than 65 years, EGPA, neurological involvement, lung involvement, significantly elevated serum creatinine (> 500µmol/L), and elevated D-dimer were associated with thrombosis in AAV patients. The model demonstrated satisfied discrimination with an AUC of 0.769 (95% CI, 0.726–0.812). MR analysis showed that EGPA could increase the risk of developing DVT and PE (OR = 1.0038, 95%CI = 1.0035–1.0041, P = 0.009). Thrombosis was not rare in Chinese patients with AAV. Renal damage and old age emerged as critical risk factors for thrombosis. EGPA might have a potential causal relationship with DVT and PE.","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"554 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140171867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two cases of venous thromboembolism in siblings after splenectomy due to a novel PROC gene mutation 两例因新型 PROC 基因突变导致的脾切除术后兄弟姐妹静脉血栓栓塞症病例
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-03-19 DOI: 10.1186/s12959-024-00597-5
Yunfang Zhang, Bo Wang, Yuxin Bai, Anxin Wang
Venous thromboembolism(VTE)is a common multifactorial disease. Anticoagulant protein deficiency is the most usual hereditary thrombophilia in the Chinese people, which includes protein C(PC), protein S and antithrombin deficiencies. A retrospective analysis was conducted on clinical manifestations, laboratory tests, genetic information, and other relevant data of siblings diagnosed with VTE in 2020 at the Department of Pediatrics of Shenzhen Second People’s Hospital. The proband, a 12-year-old female, was admitted to the hospital in December 2020 with a complaint of pain in the left lower limb for four days. The examination found that the PC activity was 53%, and B-ultrasound showed bilateral thrombosis of the great saphenous vein in the thigh segment. The proband’s younger brother, a 10-year-old male, was admitted to the hospital in January 2021 due to right lower limb pain for two weeks. PC activity is 40%. B-ultrasound showed superficial venous thrombosis in the left lower limb and upper limb. Both siblings suffered from thalassemia and underwent splenectomy before recurrent thrombosis occurred. The proband’s mother was asymptomatic, and her PC activity was 45%. Both cases were treated with warfarin anticoagulation, and their symptoms improved. The proband’s mother was found to have a heterozygous mutation at this locus through Sanger sequencing. Protein C deficiency should be considered for venous thromboembolism in childhood. The heterozygous mutation 1204 A > G in PROC exon 9 in this family is reported for the first time.
静脉血栓栓塞症(VTE)是一种常见的多因素疾病。抗凝血蛋白缺乏症是中国人最常见的遗传性血栓性疾病,包括蛋白C(PC)、蛋白S和抗凝血酶缺乏症。本研究对深圳市第二人民医院儿科2020年确诊的VTE同胞的临床表现、实验室检查、遗传信息及其他相关资料进行了回顾性分析。该患者为女性,12 岁,因左下肢疼痛 4 天于 2020 年 12 月入院。检查发现PC活动度为53%,B超显示双侧大隐静脉大腿段血栓形成。原告的弟弟,男性,10 岁,因右下肢疼痛两周于 2021 年 1 月入院。PC 活动度为 40%。B 超显示左下肢和上肢浅静脉血栓形成。两兄妹均患有地中海贫血症,并在血栓复发前接受了脾脏切除术。原发性血栓患者的母亲无症状,PC活性为45%。两个病例都接受了华法林抗凝治疗,症状均有所改善。通过桑格测序,发现该患者的母亲在该基因位点上存在杂合突变。儿童静脉血栓栓塞症应考虑蛋白 C 缺乏症。该家族首次报告了 PROC 第 9 外显子 1204 A > G 的杂合突变。
{"title":"Two cases of venous thromboembolism in siblings after splenectomy due to a novel PROC gene mutation","authors":"Yunfang Zhang, Bo Wang, Yuxin Bai, Anxin Wang","doi":"10.1186/s12959-024-00597-5","DOIUrl":"https://doi.org/10.1186/s12959-024-00597-5","url":null,"abstract":"Venous thromboembolism(VTE)is a common multifactorial disease. Anticoagulant protein deficiency is the most usual hereditary thrombophilia in the Chinese people, which includes protein C(PC), protein S and antithrombin deficiencies. A retrospective analysis was conducted on clinical manifestations, laboratory tests, genetic information, and other relevant data of siblings diagnosed with VTE in 2020 at the Department of Pediatrics of Shenzhen Second People’s Hospital. The proband, a 12-year-old female, was admitted to the hospital in December 2020 with a complaint of pain in the left lower limb for four days. The examination found that the PC activity was 53%, and B-ultrasound showed bilateral thrombosis of the great saphenous vein in the thigh segment. The proband’s younger brother, a 10-year-old male, was admitted to the hospital in January 2021 due to right lower limb pain for two weeks. PC activity is 40%. B-ultrasound showed superficial venous thrombosis in the left lower limb and upper limb. Both siblings suffered from thalassemia and underwent splenectomy before recurrent thrombosis occurred. The proband’s mother was asymptomatic, and her PC activity was 45%. Both cases were treated with warfarin anticoagulation, and their symptoms improved. The proband’s mother was found to have a heterozygous mutation at this locus through Sanger sequencing. Protein C deficiency should be considered for venous thromboembolism in childhood. The heterozygous mutation 1204 A > G in PROC exon 9 in this family is reported for the first time.","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"164 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140171772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
C-type lectin-like receptor 2: roles and drug target C 型凝集素样受体 2:作用和药物靶点
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-03-19 DOI: 10.1186/s12959-024-00594-8
Lan Sun, Zhe Wang, Zhiyan Liu, Guangyan Mu, Yimin Cui, Qian Xiang
C-type lectin-like receptor-2 (CLEC-2) is a member of the C-type lectin superfamily of cell surface receptors. The first confirmed endogenous and exogenous ligands of CLEC-2 are podoplanin and rhodocytin, respectively. CLEC-2 is expressed on the surface of platelets, which participates in platelet activation and aggregation by binding with its ligands. CLEC-2 and its ligands are involved in pathophysiological processes, such as atherosclerosis, cancer, inflammatory thrombus status, maintenance of vascular wall integrity, and cancer-related thrombosis. In the last 5 years, different anti- podoplanin antibody types have been developed for the treatment of cancers, such as glioblastoma and lung cancer. New tests and new diagnostics targeting CLEC-2 are also discussed. CLEC-2 mediates thrombosis in various pathological states, but CLEC-2-specific deletion does not affect normal hemostasis, which would provide a new therapeutic tool for many thromboembolic diseases. The CLEC-2-podoplanin interaction is a target for cancer treatment. CLEC-2 may be applied in clinical practice and play a therapeutic role.
C 型凝集素样受体-2(CLEC-2)是细胞表面受体 C 型凝集素超家族的成员。第一个被证实的 CLEC-2 内源性和外源性配体分别是 podoplanin 和 rhodocytin。CLEC-2 表达于血小板表面,通过与其配体结合参与血小板的活化和聚集。CLEC-2 及其配体参与病理生理过程,如动脉粥样硬化、癌症、炎性血栓状态、血管壁完整性的维护以及癌症相关血栓形成。在过去 5 年中,已开发出不同类型的抗 podoplanin 抗体,用于治疗胶质母细胞瘤和肺癌等癌症。此外,还讨论了针对 CLEC-2 的新测试和新诊断方法。CLEC-2在各种病理状态下介导血栓形成,但CLEC-2特异性缺失不会影响正常止血,这将为许多血栓栓塞性疾病提供新的治疗工具。CLEC-2-podoplanin相互作用是癌症治疗的一个靶点。CLEC-2可应用于临床并发挥治疗作用。
{"title":"C-type lectin-like receptor 2: roles and drug target","authors":"Lan Sun, Zhe Wang, Zhiyan Liu, Guangyan Mu, Yimin Cui, Qian Xiang","doi":"10.1186/s12959-024-00594-8","DOIUrl":"https://doi.org/10.1186/s12959-024-00594-8","url":null,"abstract":"C-type lectin-like receptor-2 (CLEC-2) is a member of the C-type lectin superfamily of cell surface receptors. The first confirmed endogenous and exogenous ligands of CLEC-2 are podoplanin and rhodocytin, respectively. CLEC-2 is expressed on the surface of platelets, which participates in platelet activation and aggregation by binding with its ligands. CLEC-2 and its ligands are involved in pathophysiological processes, such as atherosclerosis, cancer, inflammatory thrombus status, maintenance of vascular wall integrity, and cancer-related thrombosis. In the last 5 years, different anti- podoplanin antibody types have been developed for the treatment of cancers, such as glioblastoma and lung cancer. New tests and new diagnostics targeting CLEC-2 are also discussed. CLEC-2 mediates thrombosis in various pathological states, but CLEC-2-specific deletion does not affect normal hemostasis, which would provide a new therapeutic tool for many thromboembolic diseases. The CLEC-2-podoplanin interaction is a target for cancer treatment. CLEC-2 may be applied in clinical practice and play a therapeutic role.","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"21 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140171770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for venous thromboembolism in a single pediatric intensive care unit in China. 中国一家儿科重症监护病房的静脉血栓栓塞风险因素。
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-03-15 DOI: 10.1186/s12959-024-00596-6
Jintuo Zhou, Yanting Zhu, Ying Liu, Hairong Zhan, Peiguang Niu, Huajiao Chen, Jinhua Zhang

Background: Analyses of extensive, nationally representative databases indicate a rising prevalence of venous thromboembolism (VTE) among critically ill children. However, the majority of studies on childhood VTE have primarily concentrated on Caucasian populations in the United States and European countries. There is a lack of epidemiological studies on VTE in Chinese children.

Methods: We conducted a retrospective cohort study of data from the Pediatric Intensive Care (PIC) database. Data were obtained and extracted by using Structured Query Language (SQL) and the administrative platform pgAdmin4 for PostgreSQL. Bivariate analyses were conducted in which categorical variables were analyzed by a chi-square test and continuous variables were analyzed by a Student's t-test. Separate multivariable logistic regressions were employed to investigate the associations between VTE and sociodemographic factors as well as clinical factors.

Results: Our study included 12,881 pediatric patients from the PIC database, spanning the years 2010 to 2018. The incidence rate of pediatric VTE was 0.19% (24/12,881). The venous thrombotic locations were deep venous thrombosis extremities (n = 18), superior vena cava (n = 1), cerebral sinovenous (n = 1), and other deep venous thrombosis (n = 4). Univariate analysis showed that age, weight, shock, sepsis, cancer and vasopressor receipt were statistically significant risk factors for pediatric VTE (all p ≤ 0.05). After multivariable logistic regression analysis, only shock (aOR: 6.77, 95%CI: 1.33-34.73, p = 0.019) and admission for sepsis (aOR: 6.09, 95%CI: 1.76-21.09, p = 0.004) were statistically significant associated with pediatric VTE.

Conclusions: In conclusion, data obtained from the Pediatric Intensive Care (PIC) database revealed a prevalence of VTE in pediatric patients of 0.19%. The most common location for venous thrombi was deep venous thrombosis (DVT) in the extremities. We identified that shock and sepsis were statistically significant factors associated with pediatric VTE.

背景:对具有广泛全国代表性的数据库进行的分析表明,重症儿童中静脉血栓栓塞症(VTE)的发病率呈上升趋势。然而,大多数有关儿童 VTE 的研究主要集中在美国和欧洲国家的白种人群体。目前还缺乏针对中国儿童 VTE 的流行病学研究:我们对儿科重症监护(PIC)数据库中的数据进行了一项回顾性队列研究。数据通过结构化查询语言(SQL)和PostgreSQL管理平台pgAdmin4获取和提取。在进行二变量分析时,分类变量采用卡方检验,连续变量采用学生 t 检验。分别采用多变量逻辑回归研究 VTE 与社会人口学因素和临床因素之间的关系:我们的研究纳入了 PIC 数据库中的 12881 名儿科患者,时间跨度为 2010 年至 2018 年。儿科 VTE 的发病率为 0.19%(24/12881)。静脉血栓部位为四肢深静脉血栓(18例)、上腔静脉(1例)、脑窦静脉(1例)和其他深静脉血栓(4例)。单变量分析表明,年龄、体重、休克、脓毒症、癌症和接受血管加压素是小儿 VTE 的重要统计风险因素(所有 p 均小于 0.05)。经过多变量逻辑回归分析,只有休克(aOR:6.77,95%CI:1.33-34.73,p = 0.019)和因败血症入院(aOR:6.09,95%CI:1.76-21.09,p = 0.004)与小儿 VTE 有显著的统计学相关性:总之,从儿科重症监护(PIC)数据库获得的数据显示,儿科患者的 VTE 发生率为 0.19%。静脉血栓最常见的部位是四肢深静脉血栓(DVT)。我们发现,休克和败血症是与儿科 VTE 相关的重要统计学因素。
{"title":"Risk factors for venous thromboembolism in a single pediatric intensive care unit in China.","authors":"Jintuo Zhou, Yanting Zhu, Ying Liu, Hairong Zhan, Peiguang Niu, Huajiao Chen, Jinhua Zhang","doi":"10.1186/s12959-024-00596-6","DOIUrl":"10.1186/s12959-024-00596-6","url":null,"abstract":"<p><strong>Background: </strong>Analyses of extensive, nationally representative databases indicate a rising prevalence of venous thromboembolism (VTE) among critically ill children. However, the majority of studies on childhood VTE have primarily concentrated on Caucasian populations in the United States and European countries. There is a lack of epidemiological studies on VTE in Chinese children.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of data from the Pediatric Intensive Care (PIC) database. Data were obtained and extracted by using Structured Query Language (SQL) and the administrative platform pgAdmin4 for PostgreSQL. Bivariate analyses were conducted in which categorical variables were analyzed by a chi-square test and continuous variables were analyzed by a Student's t-test. Separate multivariable logistic regressions were employed to investigate the associations between VTE and sociodemographic factors as well as clinical factors.</p><p><strong>Results: </strong>Our study included 12,881 pediatric patients from the PIC database, spanning the years 2010 to 2018. The incidence rate of pediatric VTE was 0.19% (24/12,881). The venous thrombotic locations were deep venous thrombosis extremities (n = 18), superior vena cava (n = 1), cerebral sinovenous (n = 1), and other deep venous thrombosis (n = 4). Univariate analysis showed that age, weight, shock, sepsis, cancer and vasopressor receipt were statistically significant risk factors for pediatric VTE (all p ≤ 0.05). After multivariable logistic regression analysis, only shock (aOR: 6.77, 95%CI: 1.33-34.73, p = 0.019) and admission for sepsis (aOR: 6.09, 95%CI: 1.76-21.09, p = 0.004) were statistically significant associated with pediatric VTE.</p><p><strong>Conclusions: </strong>In conclusion, data obtained from the Pediatric Intensive Care (PIC) database revealed a prevalence of VTE in pediatric patients of 0.19%. The most common location for venous thrombi was deep venous thrombosis (DVT) in the extremities. We identified that shock and sepsis were statistically significant factors associated with pediatric VTE.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"22 1","pages":"26"},"PeriodicalIF":3.1,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140140778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful retrieval of tip-embedded inferior vena cava filter using a modified forceps technique: case report. 使用改良镊子技术成功取出尖端嵌入的下腔静脉过滤器:病例报告。
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-03-12 DOI: 10.1186/s12959-024-00595-7
Yang Liu, Junlong Ma, Qiqi Wang, Wei Zeng, Chunshui He

Background: The retrieval of inferior vena cava (IVC) filter is essential for preventing complications associated with the device. Advanced techniques have been developed to improve the success rate of retrieving tip-embedded filters. The forceps technique is frequently used to address this issue.

Case presentation: We present a case study of two patients who underwent a successful tip-embedded IVC filter retrieval using a modified forceps technique, which has not been previously reported. This technique involves using a wire loop under the filter tip and a forceps to grasp the filter shoulder. By pulling the wire loop and pushing the forceps in counterforce, the filter tip is straightened and aligned with the vascular sheath. The vascular sheath can then dissect the filter tip out from the caval wall and get inside the sheath to complete the retrieval.

Conclusions: The modified forceps technique we present here offers a new solution for the complex retrieval of IVC filters.

背景:取回下腔静脉(IVC)滤器对于预防与该装置相关的并发症至关重要。为了提高取回尖端嵌入滤器的成功率,人们开发了先进的技术。镊子技术常用于解决这一问题:我们对两名患者进行了病例研究,他们使用改良的镊子技术成功取回了尖端嵌入式 IVC 过滤器。该技术包括在过滤器顶端下方使用钢丝圈,并用镊子夹住过滤器肩部。通过拉动钢丝圈和反作用力推动镊子,过滤器顶端被拉直并与血管鞘对齐。然后,血管鞘可将滤器尖端从腔壁剥离,并进入鞘内完成取出:我们在此介绍的改良镊子技术为复杂的 IVC 过滤器取出术提供了一种新的解决方案。
{"title":"Successful retrieval of tip-embedded inferior vena cava filter using a modified forceps technique: case report.","authors":"Yang Liu, Junlong Ma, Qiqi Wang, Wei Zeng, Chunshui He","doi":"10.1186/s12959-024-00595-7","DOIUrl":"10.1186/s12959-024-00595-7","url":null,"abstract":"<p><strong>Background: </strong>The retrieval of inferior vena cava (IVC) filter is essential for preventing complications associated with the device. Advanced techniques have been developed to improve the success rate of retrieving tip-embedded filters. The forceps technique is frequently used to address this issue.</p><p><strong>Case presentation: </strong>We present a case study of two patients who underwent a successful tip-embedded IVC filter retrieval using a modified forceps technique, which has not been previously reported. This technique involves using a wire loop under the filter tip and a forceps to grasp the filter shoulder. By pulling the wire loop and pushing the forceps in counterforce, the filter tip is straightened and aligned with the vascular sheath. The vascular sheath can then dissect the filter tip out from the caval wall and get inside the sheath to complete the retrieval.</p><p><strong>Conclusions: </strong>The modified forceps technique we present here offers a new solution for the complex retrieval of IVC filters.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"22 1","pages":"25"},"PeriodicalIF":3.1,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10936076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140111504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban 接受利伐沙班治疗的心房颤动患者的凝血时间比(CTR)及其与治疗结果的关系
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-03-01 DOI: 10.1186/s12959-024-00591-x
Liselotte Onelöv, Elvar Theodorsson, Mojca Božič-Mijovski†, Alenka Mavri
There are situations where information about the anticoagulant effects of Rivaroxaban could be clinically useful. Methods for measuring Rivaroxaban concentrations are not available at all medical laboratories while the test MRX PT DOAC for measuring the functional effects of Rivaroxaban, in CTR (Clot Time Ratio), can be made available around the clock. The objectives of this study were to investigate CTR in trough and peak samples during Rivaroxaban treatment of atrial fibrillation and to correlate the findings to bleeding episodes. 3 trough- and 3 peak samples from 60 patients (30 on 20 mg daily and 30 on 15 mg daily) were analyzed with PT DOAC. Patients were monitored for 20 months, and bleeding and thrombotic events were documented. Descriptive statistics were used to summarize the data and non-parametric t-test for comparison between groups. ROC curves for the prediction of DOAC plasma levels > 50 ng/mL as determined with LC-MS/MS and anti-FXa methods were computed. There was a significant difference between trough and peak CTR (median CTR 1.33 vs. 3.57, p < 0.001). 28 patients suffered bleeds. Patients on 20 mg Rivaroxaban with bleeds had higher mean peak CTR than patients without bleeds (CTR 4.11 vs. CTR 3.47, p = 0.040). There was no significant difference in mean CTR between patients on 15 mg Rivaroxaban with or without bleeds (CTR 3.81 vs. 3.21, p = 0.803), or when considering all patients (CTR 3.63 vs. 3.56, p = 0.445). Five out of seven patients on Rivaroxaban 20 with mean peak CTR above the dose specific first to third quartile range (Q1-Q3) suffered bleeds, while 7/16 patients with mean peak CTR within, and 1/7 patients with mean peak CTR below the Q1-Q3 suffered bleeds. The area under the ROC curve was > 0.98 at the upper limit of the PT DOAC reference interval and the negative predictive value of PT DOAC for the prediction of DOAC plasma levels > 50 ng/mL was > 0.96. The sample size was too low to draw any firm conclusions but is seems that MRX PT DOAC might be a useful laboratory test in situations where the effect of Rivaroxaban needs evaluation.
在某些情况下,有关利伐沙班抗凝效果的信息可能对临床有用。测量利伐沙班浓度的方法并非所有医学实验室都能提供,而用于测量利伐沙班功能效应的 MRX PT DOAC(凝血时间比)测试却可以全天候提供。本研究的目的是调查利伐沙班治疗心房颤动期间谷值和峰值样本中的凝血时间比,并将调查结果与出血发作相关联。使用 PT DOAC 分析了 60 名患者(30 人每天服用 20 毫克,30 人每天服用 15 毫克)的 3 份波谷和 3 份波峰样本。对患者进行了长达 20 个月的监测,并记录了出血和血栓事件。描述性统计用于总结数据,非参数 t 检验用于组间比较。计算了用LC-MS/MS和抗FXa方法测定的DOAC血浆水平> 50纳克/毫升的预测ROC曲线。在 PT DOAC 参考区间的上限,谷值和峰值 CTR 之间存在显著差异(中位数 CTR 1.33 vs. 3.57,p 0.98),PT DOAC 预测 DOAC 血浆水平 > 50 ng/mL 的阴性预测值 > 0.96。样本量太少,无法得出任何确切结论,但在需要评估利伐沙班效果的情况下,MRX PT DOAC似乎是一种有用的实验室检测方法。
{"title":"Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban","authors":"Liselotte Onelöv, Elvar Theodorsson, Mojca Božič-Mijovski†, Alenka Mavri","doi":"10.1186/s12959-024-00591-x","DOIUrl":"https://doi.org/10.1186/s12959-024-00591-x","url":null,"abstract":"There are situations where information about the anticoagulant effects of Rivaroxaban could be clinically useful. Methods for measuring Rivaroxaban concentrations are not available at all medical laboratories while the test MRX PT DOAC for measuring the functional effects of Rivaroxaban, in CTR (Clot Time Ratio), can be made available around the clock. The objectives of this study were to investigate CTR in trough and peak samples during Rivaroxaban treatment of atrial fibrillation and to correlate the findings to bleeding episodes. 3 trough- and 3 peak samples from 60 patients (30 on 20 mg daily and 30 on 15 mg daily) were analyzed with PT DOAC. Patients were monitored for 20 months, and bleeding and thrombotic events were documented. Descriptive statistics were used to summarize the data and non-parametric t-test for comparison between groups. ROC curves for the prediction of DOAC plasma levels > 50 ng/mL as determined with LC-MS/MS and anti-FXa methods were computed. There was a significant difference between trough and peak CTR (median CTR 1.33 vs. 3.57, p < 0.001). 28 patients suffered bleeds. Patients on 20 mg Rivaroxaban with bleeds had higher mean peak CTR than patients without bleeds (CTR 4.11 vs. CTR 3.47, p = 0.040). There was no significant difference in mean CTR between patients on 15 mg Rivaroxaban with or without bleeds (CTR 3.81 vs. 3.21, p = 0.803), or when considering all patients (CTR 3.63 vs. 3.56, p = 0.445). Five out of seven patients on Rivaroxaban 20 with mean peak CTR above the dose specific first to third quartile range (Q1-Q3) suffered bleeds, while 7/16 patients with mean peak CTR within, and 1/7 patients with mean peak CTR below the Q1-Q3 suffered bleeds. The area under the ROC curve was > 0.98 at the upper limit of the PT DOAC reference interval and the negative predictive value of PT DOAC for the prediction of DOAC plasma levels > 50 ng/mL was > 0.96. The sample size was too low to draw any firm conclusions but is seems that MRX PT DOAC might be a useful laboratory test in situations where the effect of Rivaroxaban needs evaluation.","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"11 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140003138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative effectiveness and safety of DOACs vs. VKAs in treatment of left ventricular thrombus- a meta-analysis update DOACs 与 VKAs 治疗左心室血栓的有效性和安全性比较--最新荟萃分析
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-03-01 DOI: 10.1186/s12959-024-00585-9
Tong Hu, Changli Chen, Kellina Maduray, Wenqiang Han, Tongshuai Chen, Jingquan Zhong
Left ventricular thrombus (LVT) formation in patients with acute myocardial infarction (AMI) or cardiomyopathies is not uncommon. The optimal oral anticoagulation therapy for resolving LVT has been under intense debate. Vitamin K antagonists (VKAs) remain the anticoagulant of choice for this condition, according to practice guidelines. Evidence supporting the use of direct oral anticoagulants (DOACs) in the management of LVT continues to grow. We performed a systematic review and meta-analysis to compare the efficacy and safety of DOACs versus VKAs. A comprehensive literature search was carried out in PubMed, Cochrane Library, Web of Science, Embase, and Scopus databases in July 2023. The efficacy outcomes of this study were thrombus resolution, ischemic stroke, systemic embolism, stroke/systemic embolism, all-cause mortality, and adverse cardiovascular events. The safety outcomes were any bleeding, major bleeding, and intracranial hemorrhage. A total of twenty-seven eligible studies were included in the meta-analysis. Data were analyzed utilizing Stata software version 15.1. There was no significant difference between DOACs and VKAs with regard to LVT resolution (RR = 1.00, 95% CI 0.95–1.05, P = 0.99). In the overall analysis, DOACs significantly reduced the risk of stroke (RR = 0.74, 95% CI 0.57–0.96, P = 0.021), all-cause mortality (RR = 0.70, 95% CI 0.57–0.86, P = 0.001), any bleeding (RR = 0.75, 95% CI 0.61–0.92, P = 0.006) and major bleeding (RR = 0.67, 95% CI 0.52–0.85, P = 0.001) when compared to VKAs. Meanwhile, in the sub-analysis examining randomized controlled trials (RCTs), the aforementioned outcomes no longer differed significantly between the DOACs and VKAs groups. The incidences of systemic embolism (RR = 0.81, 95% CI 0.54–1.22, P = 0.32), stroke/systemic embolism (RR = 0.85, 95% CI 0.72–1.00, P = 0.056), intracranial hemorrhage (RR = 0.59, 95% CI 0.23–1.54, P = 0.28), and adverse cardiovascular events (RR = 0.99, 95% CI 0.63–1.56, P = 0.92) were comparable between the DOACs and VKAs groups. A subgroup analysis showed that patients treated with rivaroxaban had a significantly lower risk of stroke (RR = 0.24, 95% CI 0.08–0.72, P = 0.011) than those in the VKAs group. With non-inferior efficacy and superior safety, DOACs are promising therapeutic alternatives to VKAs in the treatment of LVT. Further robust investigations are warranted to confirm our findings.
急性心肌梗死(AMI)或心肌病患者左心室血栓(LVT)的形成并不少见。解决左心室血栓的最佳口服抗凝疗法一直备受争议。根据实践指南,维生素 K 拮抗剂 (VKAs) 仍是治疗这种情况的首选抗凝剂。支持使用直接口服抗凝剂(DOACs)治疗 LVT 的证据不断增加。我们进行了一项系统综述和荟萃分析,以比较 DOAC 与 VKAs 的疗效和安全性。我们于 2023 年 7 月在 PubMed、Cochrane Library、Web of Science、Embase 和 Scopus 数据库中进行了全面的文献检索。本研究的疗效指标为血栓溶解、缺血性中风、全身性栓塞、中风/全身性栓塞、全因死亡率和不良心血管事件。安全性结果为任何出血、大出血和颅内出血。共有 27 项符合条件的研究被纳入荟萃分析。数据采用Stata软件15.1版进行分析。DOACs 和 VKAs 在 LVT 解救方面无明显差异(RR = 1.00,95% CI 0.95-1.05,P = 0.99)。在总体分析中,与 VKAs 相比,DOACs 能显著降低卒中风险(RR = 0.74,95% CI 0.57-0.96,P = 0.021)、全因死亡率(RR = 0.70,95% CI 0.57-0.86,P = 0.001)、任何出血(RR = 0.75,95% CI 0.61-0.92,P = 0.006)和大出血(RR = 0.67,95% CI 0.52-0.85,P = 0.001)。同时,在研究随机对照试验(RCT)的子分析中,DOACs 组和 VKAs 组的上述结果不再有显著差异。全身性栓塞(RR = 0.81,95% CI 0.54-1.22,P = 0.32)、卒中/全身性栓塞(RR = 0.85,95% CI 0.72-1.00,P = 0.056)、颅内出血(RR = 0.59,95% CI 0.23-1.54,P = 0.28)和不良心血管事件(RR = 0.99,95% CI 0.63-1.56,P = 0.92)在 DOACs 组和 VKAs 组之间具有可比性。一项亚组分析显示,接受利伐沙班治疗的患者发生中风的风险(RR = 0.24,95% CI 0.08-0.72,P = 0.011)明显低于VKAs组。DOACs具有非劣效性和优越的安全性,是治疗LVT的VKAs的有前途的替代治疗药物。为了证实我们的研究结果,有必要进行进一步的深入研究。
{"title":"Comparative effectiveness and safety of DOACs vs. VKAs in treatment of left ventricular thrombus- a meta-analysis update","authors":"Tong Hu, Changli Chen, Kellina Maduray, Wenqiang Han, Tongshuai Chen, Jingquan Zhong","doi":"10.1186/s12959-024-00585-9","DOIUrl":"https://doi.org/10.1186/s12959-024-00585-9","url":null,"abstract":"Left ventricular thrombus (LVT) formation in patients with acute myocardial infarction (AMI) or cardiomyopathies is not uncommon. The optimal oral anticoagulation therapy for resolving LVT has been under intense debate. Vitamin K antagonists (VKAs) remain the anticoagulant of choice for this condition, according to practice guidelines. Evidence supporting the use of direct oral anticoagulants (DOACs) in the management of LVT continues to grow. We performed a systematic review and meta-analysis to compare the efficacy and safety of DOACs versus VKAs. A comprehensive literature search was carried out in PubMed, Cochrane Library, Web of Science, Embase, and Scopus databases in July 2023. The efficacy outcomes of this study were thrombus resolution, ischemic stroke, systemic embolism, stroke/systemic embolism, all-cause mortality, and adverse cardiovascular events. The safety outcomes were any bleeding, major bleeding, and intracranial hemorrhage. A total of twenty-seven eligible studies were included in the meta-analysis. Data were analyzed utilizing Stata software version 15.1. There was no significant difference between DOACs and VKAs with regard to LVT resolution (RR = 1.00, 95% CI 0.95–1.05, P = 0.99). In the overall analysis, DOACs significantly reduced the risk of stroke (RR = 0.74, 95% CI 0.57–0.96, P = 0.021), all-cause mortality (RR = 0.70, 95% CI 0.57–0.86, P = 0.001), any bleeding (RR = 0.75, 95% CI 0.61–0.92, P = 0.006) and major bleeding (RR = 0.67, 95% CI 0.52–0.85, P = 0.001) when compared to VKAs. Meanwhile, in the sub-analysis examining randomized controlled trials (RCTs), the aforementioned outcomes no longer differed significantly between the DOACs and VKAs groups. The incidences of systemic embolism (RR = 0.81, 95% CI 0.54–1.22, P = 0.32), stroke/systemic embolism (RR = 0.85, 95% CI 0.72–1.00, P = 0.056), intracranial hemorrhage (RR = 0.59, 95% CI 0.23–1.54, P = 0.28), and adverse cardiovascular events (RR = 0.99, 95% CI 0.63–1.56, P = 0.92) were comparable between the DOACs and VKAs groups. A subgroup analysis showed that patients treated with rivaroxaban had a significantly lower risk of stroke (RR = 0.24, 95% CI 0.08–0.72, P = 0.011) than those in the VKAs group. With non-inferior efficacy and superior safety, DOACs are promising therapeutic alternatives to VKAs in the treatment of LVT. Further robust investigations are warranted to confirm our findings.","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"257 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140011528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of early prophylaxis for deep-vein thrombosis in intracerebral hemorrhage patients: an observational study from the Chinese Stroke Center Alliance. 脑出血患者深静脉血栓早期预防的实施:来自中国卒中中心联盟的观察性研究。
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-02-28 DOI: 10.1186/s12959-024-00592-w
Ran Zhang, Weige Sun, Yana Xing, Yongjun Wang, Zixiao Li, Liping Liu, Hongqiu Gu, Kaixuan Yang, Xin Yang, Chunjuan Wang, Qingbo Liu, Qian Xiao, Weixin Cai

Background: There is substantial evidence to support the use of several methods for preventing deep-vein thrombosis (DVT) following intracerebral hemorrhage (ICH). However, the extent to which these measures are implemented in clinical practice and the factors influencing patients' receipt of preventive measures remain unclear. Therefore, we aimed to evaluate the rate of the early implementation of DVT prophylaxis and the factors associated with its success in patients with ICH.

Methods: This study enrolled 49,950 patients with spontaneous ICH from the Chinese Stroke Center Alliance (CSCA) between August 2015 and July 2019. Early DVT prophylaxis implementation was defined as an intervention occurring within 48 h after admission. Univariate and multivariate logistic regression analyses were conducted to identify the rate and factors associated with the implementation of early prophylaxis for DVT in patients with ICH.

Results: Among the 49,950 ICH patients, the rate of early DVT prophylaxis implementation was 49.9%, the rate of early mobilization implementation was 29.49%, and that of pharmacological prophylaxis was 2.02%. Factors associated with an increased likelihood of early DVT prophylaxis being administered in the multivariable model included receiving early rehabilitation therapy (odds ratio [OR], 2.531); admission to stroke unit (OR 2.231); admission to intensive care unit (OR 1.975); being located in central (OR 1.879) or eastern regions (OR 1.529); having a history of chronic obstructive pulmonary disease (OR 1.292), ischemic stroke (OR 1.245), coronary heart disease or myocardial infarction (OR 1.2); taking antihypertensive drugs (OR 1.136); and having a higher Glasgow Coma Scale (GCS) score (OR 1.045). Conversely, being male (OR 0.936), being hospitalized in tertiary hospitals (OR 0.778), and having a previous intracranial hemorrhage (OR 0.733) were associated with a lower likelihood of early DVT prophylaxis being administered in patients with ICH.

Conclusions: The implementation rate of early DVT prophylaxis among Chinese patients with ICH was subpar, with pharmacological prophylaxis showing the lowest prevalence. Various controllable factors exerted an impact on the implementation of early DVT prophylaxis in this population.

背景:有大量证据支持使用多种方法预防脑内出血(ICH)后深静脉血栓形成(DVT)。然而,这些措施在临床实践中的实施程度以及影响患者接受预防措施的因素仍不清楚。因此,我们旨在评估 ICH 患者早期实施深静脉血栓预防措施的比率及其成功的相关因素:本研究在2015年8月至2019年7月期间,从中国卒中中心联盟(CSCA)招募了49950名自发性ICH患者。早期深静脉血栓预防措施的实施被定义为入院后 48 小时内进行的干预。研究人员进行了单变量和多变量逻辑回归分析,以确定ICH患者实施深静脉血栓早期预防的比率和相关因素:在 49,950 名 ICH 患者中,早期预防深静脉血栓的实施率为 49.9%,早期动员的实施率为 29.49%,药物预防的实施率为 2.02%。在多变量模型中,与早期实施深静脉血栓预防可能性增加相关的因素包括:接受早期康复治疗(几率比 [OR],2.531);入住卒中单元(OR 2.231);入住重症监护单元(OR 1.975);位于中部地区(OR 1.879)或东部地区(OR 1.529);有慢性阻塞性肺病(OR 1.292)、缺血性中风(OR 1.245)、冠心病或心肌梗死(OR 1.2)病史;服用降压药(OR 1.136);格拉斯哥昏迷量表(GCS)评分较高(OR 1.045)。相反,男性(OR 0.936)、在三级医院住院(OR 0.778)和曾有过颅内出血(OR 0.733)与 ICH 患者接受早期深静脉血栓预防的可能性较低有关:结论:中国 ICH 患者早期预防深静脉血栓形成的实施率较低,其中药物预防的实施率最低。各种可控因素对该人群实施早期深静脉血栓预防措施产生了影响。
{"title":"Implementation of early prophylaxis for deep-vein thrombosis in intracerebral hemorrhage patients: an observational study from the Chinese Stroke Center Alliance.","authors":"Ran Zhang, Weige Sun, Yana Xing, Yongjun Wang, Zixiao Li, Liping Liu, Hongqiu Gu, Kaixuan Yang, Xin Yang, Chunjuan Wang, Qingbo Liu, Qian Xiao, Weixin Cai","doi":"10.1186/s12959-024-00592-w","DOIUrl":"10.1186/s12959-024-00592-w","url":null,"abstract":"<p><strong>Background: </strong>There is substantial evidence to support the use of several methods for preventing deep-vein thrombosis (DVT) following intracerebral hemorrhage (ICH). However, the extent to which these measures are implemented in clinical practice and the factors influencing patients' receipt of preventive measures remain unclear. Therefore, we aimed to evaluate the rate of the early implementation of DVT prophylaxis and the factors associated with its success in patients with ICH.</p><p><strong>Methods: </strong>This study enrolled 49,950 patients with spontaneous ICH from the Chinese Stroke Center Alliance (CSCA) between August 2015 and July 2019. Early DVT prophylaxis implementation was defined as an intervention occurring within 48 h after admission. Univariate and multivariate logistic regression analyses were conducted to identify the rate and factors associated with the implementation of early prophylaxis for DVT in patients with ICH.</p><p><strong>Results: </strong>Among the 49,950 ICH patients, the rate of early DVT prophylaxis implementation was 49.9%, the rate of early mobilization implementation was 29.49%, and that of pharmacological prophylaxis was 2.02%. Factors associated with an increased likelihood of early DVT prophylaxis being administered in the multivariable model included receiving early rehabilitation therapy (odds ratio [OR], 2.531); admission to stroke unit (OR 2.231); admission to intensive care unit (OR 1.975); being located in central (OR 1.879) or eastern regions (OR 1.529); having a history of chronic obstructive pulmonary disease (OR 1.292), ischemic stroke (OR 1.245), coronary heart disease or myocardial infarction (OR 1.2); taking antihypertensive drugs (OR 1.136); and having a higher Glasgow Coma Scale (GCS) score (OR 1.045). Conversely, being male (OR 0.936), being hospitalized in tertiary hospitals (OR 0.778), and having a previous intracranial hemorrhage (OR 0.733) were associated with a lower likelihood of early DVT prophylaxis being administered in patients with ICH.</p><p><strong>Conclusions: </strong>The implementation rate of early DVT prophylaxis among Chinese patients with ICH was subpar, with pharmacological prophylaxis showing the lowest prevalence. Various controllable factors exerted an impact on the implementation of early DVT prophylaxis in this population.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"22 1","pages":"22"},"PeriodicalIF":3.1,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10900581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishment and validation of a nomogram predicting the risk of deep vein thrombosis before total knee arthroplasty. 建立并验证预测全膝关节置换术前深静脉血栓风险的提名图。
IF 3.1 4区 医学 Q2 HEMATOLOGY Pub Date : 2024-02-16 DOI: 10.1186/s12959-024-00588-6
Zehua Wang, Xingjia Mao, Zijian Guo, Guoyu Che, Changxin Xiang, Chuan Xiang

Purpose: This study aimed to analyze the independent risk factors contributing to preoperative DVT in TKA and constructed a predictive nomogram to accurately evaluate its occurrence based on these factors.

Methods: The study encompassed 496 patients who underwent total knee arthroplasty at our hospital between June 2022 and June 2023. The dataset was randomly divided into a training set (n = 348) and a validation set (n = 148) in a 7:3 ratio. The least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression analysis were used to screen the predictors of preoperative DVT occurrence in TKA and construct a nomogram. The performance of the predictive models was evaluated using the concordance index (C-index), calibration curves, and the receiver operating characteristic (ROC) curves. Decision curve analysis was used to analyze the clinical applicability of nomogram.

Results: A total of 496 patients who underwent TKA were included in this study, of which 28 patients were examined for lower extremity DVT preoperatively. Platelet crit, Platelet distribution width, Procalcitonin, prothrombin time, and D-dimer were predictors of preoperative occurrence of lower extremity DVT in the nomograms of the TKA patients. In addition, the areas under the curve of the ROC of the training and validation sets were 0.935 (95%CI: 0.880-0.990) and 0.854 (95%CI: 0.697-1.000), and the C-indices of the two sets were 0.919 (95%CI: 0.860-0.978) and 0.900 (95%CI: 0.791-1.009). The nomogram demonstrated precise risk prediction of preoperative DVT occurrence in TKA as confirmed by the calibration curve and decision curve analysis.

Conclusions: This Nomogram demonstrates great differentiation, calibration and clinical validity. By assessing individual risk, clinicians can promptly detect the onset of DVT, facilitating additional life monitoring and necessary medical interventions to prevent the progression of DVT effectively.

目的:本研究旨在分析导致全膝关节置换术术前深静脉血栓形成的独立风险因素,并根据这些因素构建预测提名图,以准确评估其发生率:研究对象为2022年6月至2023年6月期间在我院接受全膝关节置换术的496例患者。数据集按 7:3 的比例随机分为训练集(n = 348)和验证集(n = 148)。使用最小绝对收缩和选择算子(LASSO)和多变量逻辑回归分析筛选 TKA 术前深静脉血栓发生的预测因素并构建提名图。使用一致性指数(C-index)、校准曲线和接收者操作特征曲线(ROC)对预测模型的性能进行了评估。决策曲线分析用于分析提名图的临床适用性:本研究共纳入了 496 例接受 TKA 的患者,其中 28 例患者在术前接受了下肢深静脉血栓检查。在 TKA 患者的提名图中,血小板临界值、血小板分布宽度、降钙素原、凝血酶原时间和 D-二聚体是术前发生下肢深静脉血栓的预测因子。此外,训练集和验证集的 ROC 曲线下面积分别为 0.935(95%CI:0.880-0.990)和 0.854(95%CI:0.697-1.000),两组的 C 指数分别为 0.919(95%CI:0.860-0.978)和 0.900(95%CI:0.791-1.009)。校准曲线和决策曲线分析证实,提名图能精确预测 TKA 术前深静脉血栓发生的风险:该提名图具有很高的区分度、校准性和临床有效性。通过评估个体风险,临床医生可以及时发现深静脉血栓的发生,便于进行额外的生命监测和必要的医疗干预,从而有效预防深静脉血栓的恶化。
{"title":"Establishment and validation of a nomogram predicting the risk of deep vein thrombosis before total knee arthroplasty.","authors":"Zehua Wang, Xingjia Mao, Zijian Guo, Guoyu Che, Changxin Xiang, Chuan Xiang","doi":"10.1186/s12959-024-00588-6","DOIUrl":"10.1186/s12959-024-00588-6","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to analyze the independent risk factors contributing to preoperative DVT in TKA and constructed a predictive nomogram to accurately evaluate its occurrence based on these factors.</p><p><strong>Methods: </strong>The study encompassed 496 patients who underwent total knee arthroplasty at our hospital between June 2022 and June 2023. The dataset was randomly divided into a training set (n = 348) and a validation set (n = 148) in a 7:3 ratio. The least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression analysis were used to screen the predictors of preoperative DVT occurrence in TKA and construct a nomogram. The performance of the predictive models was evaluated using the concordance index (C-index), calibration curves, and the receiver operating characteristic (ROC) curves. Decision curve analysis was used to analyze the clinical applicability of nomogram.</p><p><strong>Results: </strong>A total of 496 patients who underwent TKA were included in this study, of which 28 patients were examined for lower extremity DVT preoperatively. Platelet crit, Platelet distribution width, Procalcitonin, prothrombin time, and D-dimer were predictors of preoperative occurrence of lower extremity DVT in the nomograms of the TKA patients. In addition, the areas under the curve of the ROC of the training and validation sets were 0.935 (95%CI: 0.880-0.990) and 0.854 (95%CI: 0.697-1.000), and the C-indices of the two sets were 0.919 (95%CI: 0.860-0.978) and 0.900 (95%CI: 0.791-1.009). The nomogram demonstrated precise risk prediction of preoperative DVT occurrence in TKA as confirmed by the calibration curve and decision curve analysis.</p><p><strong>Conclusions: </strong>This Nomogram demonstrates great differentiation, calibration and clinical validity. By assessing individual risk, clinicians can promptly detect the onset of DVT, facilitating additional life monitoring and necessary medical interventions to prevent the progression of DVT effectively.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"22 1","pages":"21"},"PeriodicalIF":3.1,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10873976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Thrombosis Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1